Diffuse Large B-Cell Lymphoma (PORTIA)
Phase Ib, Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Patients.
|This study is recruiting: Phase Ib||Actual Start Date: [October 9, 2018]||Estimated Completion Date: [September 8, 2023]||Novartis Reference Number: CCTL019J2101|
|Condition: Diffuse Large B-Cell Lymphoma
||Interventions: tisagenlecleucel, pembrolizumab||Estimated Enrollment: [32 participants]||ClinicalTrials.gov Identifier: NCT03630159|
|This study is recruiting: Phase Ib||Actual Start Date: [October 9, 2018]|
|Estimated Completion Date: [September 8, 2023]||Novartis Reference Number: CCTL019J2101|
|Condition: Diffuse Large B-Cell Lymphoma (DLBCL)||Interventions: tisagenlecleucel, pembrolizumab|
|Estimated Enrollment: [32 participants]||ClinicalTrials.gov Identifier: NCT03630159|
A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The study will consist of 2 parts: dose timing selection part and expansion part.
Participants may be eligible to participate if they:
- Are ≥ 18 years of age
- Have confirmed relapsed or refractory DLBCL, and
- Received ≥ 2 lines of systemic therapy, including anti-CD20 and anthracycline-based chemotherapy
- Progressed after or not eligible for autologous stem cell transplant
- Meet other eligibility criteria
Find a Trial Site Location
To find a list of all our recruiting site locations, enter your address below.
Still Have a Question?
Are you a Patient or Caregiver looking for more information?
Are you a Health Care Professional looking for more information?
To view eligibility requirements for this trial, arms and interventions, trial sites and study design, please click to visit this trial on www.clinicaltrials.gov.
ASCT - autologous stem cell transplant, CD20 - Cluster of differentiation 20, DLBCL - Diffuse Large B-Cell Lymphoma, r/r - Relapsed/Refractory
Last Updated: May 1, 2019